A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer

Clinical trial NCT05818683 · RECRUITING

Trial details

NCT number: NCT05818683
Sponsor: Janssen Research & Development, LLC
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Metastatic Castration-resistant Prostate Neoplasms Metastatic Hormone-sensitive Prostate Cancer

Start date: 2023-04-26
Primary completion: 2027-08-31
Enrollment: 300

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.